Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Macrophi Inc. is currently navigating the patent prosecution process with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active case is assigned to 1 distinct examiner and is located within 1 distinct art unit. Such a structure indicates that the company's current legal focus is highly centralized within a specific administrative niche of the patent office.
The busiest examiner for this portfolio is JONES-FOSTER, ERICA NICOLE, who is currently overseeing 1 pending office action. Because the total count of pending actions is 1, this examiner is responsible for the entirety of the company's active matters. This concentration means that the prosecution progress is subject to the review of a single official. There is no distribution of the workload across multiple examiners at this stage.
The presence of 1 distinct art unit further confirms the narrow scope of the current active filings. Practitioners should observe that the 1 to 1 ratio between the busiest examiner's pending cases and the total portfolio workload leaves no room for examiner diversification. The strategy remains focused on the Biotechnology & Pharmaceuticals sector through this single channel, requiring a targeted approach to the assigned examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES-FOSTER, ERICA NICOLE | 1 | 49.4% | +44.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17761373 | LIPOPOLYSACCHARIDE PRODUCTION METHOD | JONES-FOSTER, ERICA NICOLE | 47d |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17761373 | LIPOPOLYSACCHARIDE PRODUCTION METHOD | JONES-FOSTER, ERICA NICOLE | 1656 | §103 | Non-Final OA | 47d | Pending | Mar 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMacrophi Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Erica Nicole Jones-Foster has the most, with 1 of Macrophi Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
